Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - cyproterone acetate 2 mg; ethinylestradiol 35 µg - cyproterone and estrogen

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - cyproterone acetate 2 mg; ethinylestradiol 35 µg - cyproterone and estrogen

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - cyproterone acetate 2 mg; ethinylestradiol 35 µg - cyproterone and estrogen

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - cyproterone acetate 2 mg; ethinylestradiol 35 µg - cyproterone and estrogen

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ethinylestradiol, quantity: 35 microgram; cyproterone acetate, quantity: 2 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree.,katie-35ed will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications),if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - cyproterone acetate 2mg;  ;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg     ethinylestradiol 0.035mg   excipient: hypromellose lactose monohydrate magnesium stearate povidone propylene glycol purified talc   quinoline yellow starch titanium dioxide - androgen-dependent diseases in women are an indication for treatment with ginet-63. these diseases may include: acne (where local treatment or oral antibiotics alone have not been successful), especially pronounced forms of acne that may be accompanied by inflammation or formation of nodes (acne nodulocystica, acne papulopustulosa), seborrhea, mild forms of hirsutism and/or androgenic alopecia. oral contraception in women requiring treatment for these androgen-dependent diseases is an indication for treatment with ginet-63. however ginet-63 is not recommended in women solely for contraception.

Malta - English - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - cyproterone acetate - tablet - cyproterone acetate 50 mg - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - cyproterone acetate -